Abstract 11322: Drug Eluting Stents With Biodegradable Polymer: Do They Reduce Stent Thrombosis During the First Year After Implantation? A Meta-Analysis of Seven Randomized Trials
Introduction: one of the proposed advantages of the new generation of drug eluting stents (DES) is the presence of a biodegradable polymer, which could reduce the rate of stent thrombosis. We assessed the hypothesis that DES with biodegradable polymer (DES-BP) would reduce stent thrombosis rate during the first year after implantation compared to DES with a persistent polymer (DES-PP).
Methods: we performed a meta-analysis of 7 randomized clinical trials comparing DES-BP and DES-PP, including overall 6999 patients.
Results: No significant difference in the stent thrombosis rate was found during the first year between DES-BP and DES-PP (1.16% vs. 1.23%, respectively; p = 0.96; OR 1.01, 95%CI 0.66 – 1.50; see figure); or during months 2–12 (0.27% vs. 0.45%, respectively; p = 0.33; OR 0.68; 95%CI 0.32 – 1.48).
Conclusions: during the first year after implantation, stent thrombosis rate is not reduced with the new DES-BP compared to DES-PP. The potential benefits of these new devices regarding stent thrombosis rate, therefore, should be evaluated in studies with longer-term follow-up.
- © 2010 by American Heart Association, Inc.